Oppenheimer set a $14.00 price objective on TherapeuticsMD (NASDAQ:TXMD) in a research report released on Wednesday morning. The brokerage currently has a buy rating on the stock.

Several other analysts have also commented on the company. Zacks Investment Research raised TherapeuticsMD from a hold rating to a buy rating and set a $6.25 target price on the stock in a report on Wednesday, October 17th. Cantor Fitzgerald set a $27.00 target price on TherapeuticsMD and gave the stock a buy rating in a report on Sunday, October 14th. ValuEngine raised TherapeuticsMD from a hold rating to a buy rating in a report on Friday, September 21st. Finally, BidaskClub raised TherapeuticsMD from a strong sell rating to a sell rating in a report on Wednesday, August 29th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. TherapeuticsMD currently has an average rating of Buy and a consensus price target of $13.45.

Shares of TXMD stock traded down $0.04 during mid-day trading on Wednesday, reaching $4.93. The stock had a trading volume of 1,868,728 shares, compared to its average volume of 3,371,973. The company has a debt-to-equity ratio of 0.94, a current ratio of 7.88 and a quick ratio of 7.79. TherapeuticsMD has a 1-year low of $4.30 and a 1-year high of $7.66.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Wednesday, November 7th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06. The business had revenue of $3.47 million for the quarter, compared to analyst estimates of $4.43 million. TherapeuticsMD had a negative return on equity of 109.28% and a negative net margin of 757.59%. The company’s revenue was down 21.5% on a year-over-year basis. During the same period in the prior year, the company earned ($0.07) earnings per share. As a group, equities analysts predict that TherapeuticsMD will post -0.63 earnings per share for the current fiscal year.

In related news, CEO Robert G. Finizio sold 184,000 shares of the firm’s stock in a transaction dated Friday, October 26th. The stock was sold at an average price of $5.28, for a total transaction of $971,520.00. Following the sale, the chief executive officer now directly owns 18,485,559 shares of the company’s stock, valued at $97,603,751.52. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider John C.K. Iv Milligan sold 250,000 shares of the firm’s stock in a transaction dated Wednesday, October 24th. The stock was sold at an average price of $5.35, for a total value of $1,337,500.00. Following the sale, the insider now directly owns 1,597,419 shares in the company, valued at $8,546,191.65. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 2,158,800 shares of company stock worth $12,946,562. 22.85% of the stock is owned by corporate insiders.

A number of hedge funds have recently modified their holdings of TXMD. FMR LLC boosted its position in TherapeuticsMD by 14.7% during the third quarter. FMR LLC now owns 12,049,988 shares of the company’s stock worth $79,048,000 after purchasing an additional 1,542,987 shares in the last quarter. BlackRock Inc. boosted its position in TherapeuticsMD by 10.6% during the third quarter. BlackRock Inc. now owns 16,070,569 shares of the company’s stock worth $105,421,000 after purchasing an additional 1,537,045 shares in the last quarter. Public Employees Retirement Association of Colorado boosted its position in TherapeuticsMD by 2,545.7% during the second quarter. Public Employees Retirement Association of Colorado now owns 1,071,500 shares of the company’s stock worth $6,686,000 after purchasing an additional 1,031,000 shares in the last quarter. AXA boosted its position in TherapeuticsMD by 37.8% during the third quarter. AXA now owns 1,463,274 shares of the company’s stock worth $9,599,000 after purchasing an additional 401,228 shares in the last quarter. Finally, OppenheimerFunds Inc. boosted its position in TherapeuticsMD by 17.4% during the second quarter. OppenheimerFunds Inc. now owns 1,932,439 shares of the company’s stock worth $12,058,000 after purchasing an additional 286,123 shares in the last quarter. Institutional investors own 66.20% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Read More: Understanding Relative Strength Index

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.